New study on IGF-1 by researchers at the Seaver Autism Center

Drs. Ozlem Bozdagi Gunal, Teresa Tavassoli, and Joseph D. Buxbaum have recently published a study in Molecular Autism detailing their observation of injections of human insulin-like growth factor-1 (IGF-1) in to a mouse model of ASD and of developmental delay, which they had previously reported in Shank-3 deficient mice. They observed significant beneficial effects, and given the extensive safety data for IGF-1 in children with short stature due to primary IGF-1 deficiency, IGF-1 is an attractive candidate for controlled clinical trials in SHANK3-deficiency and in ASD. Click here to read more.

To view all News and Events, click here.

This entry was posted in News. Bookmark the permalink.